No Data
No Data
No Data
No Data
No Data
Express News | Shuangcheng Pharmaceutical: Octreotide acetate injection ANDA obtained marketing approval from the US FDA
BreakingsMay 6 16:15
Shuangcheng Pharmaceutical (002693.SZ): Net loss of 8.7427 million yuan in the first quarter
Gelonghui, April 29 | Shuangcheng Pharmaceutical (002693.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 42.7617 million yuan, a year-on-year decrease of 47.52%; net profit attributable to shareholders of listed companies - 8.7427 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 9.0527 million yuan; basic earnings per share - 0.0211 yuan.
Gelonghui FinanceApr 29 22:11
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
The CRO concept was active at the beginning of the market. Baihua Pharmaceutical rose more than 8%, Boji Pharmaceutical rose 7%, and Shuangcheng Pharmaceutical, Haofan Biotech, and Yaben Chemical followed suit.
Zhitong FinanceApr 25 09:36
Express News | Shuangcheng Pharmaceutical: The company passed the US FDA on-site inspection
BreakingsApr 24 21:39
Express News | Shuangcheng Pharmaceutical: The company obtained a drug registration certificate for injectable bortezomib
BreakingsApr 15 16:31
Hainan Shuangcheng Pharma's Unit Gets Green Light to Market Pregabalin Capsules
Ningbo Shuangcheng Pharmaceutical, a unit of Hainan Shuangcheng Pharmaceutical (SHE:002693), obtained approval from China's National Medical Products Administration to register pregabalin capsules for
MT NewswiresMar 18 16:26
No Data
No Data